Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Company Overview - Harmony Biosciences Holdings, Inc. (HRMY) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with a consensus EPS estimate of $0.82, reflecting a +310% change [1][3] - Revenue expectations stand at $203.38 million, which is a 17.7% increase from the same quarter last year [3] Earnings Expectations - The earnings report is anticipated to be released on August 5, and the stock may rise if actual results exceed expectations; conversely, a miss could lead to a decline [2] - The consensus EPS estimate has been revised down by 5.2% over the last 30 days, indicating a bearish sentiment among analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Harmony Biosciences is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.31%, which complicates predictions of an earnings beat [12] - Despite the negative Earnings ESP, the company holds a Zacks Rank of 2 (Buy), suggesting potential for positive performance [12] Historical Performance - In the last reported quarter, Harmony Biosciences had an earnings surprise of +32.20%, with actual earnings of $0.78 per share compared to an expected $0.59 [13] - The company has successfully beaten consensus EPS estimates in the last four quarters [14] Industry Context - In the broader Zacks Medical - Biomedical and Genetics industry, Vertex Pharmaceuticals (VRTX) is also expected to report strong earnings, with an EPS estimate of $4.24, reflecting a +133.1% year-over-year change and revenues of $2.89 billion, up 9.2% [18][19] - Vertex has an Earnings ESP of +1.55% and a Zacks Rank of 3 (Hold), indicating a likelihood of beating the consensus EPS estimate [19][20]